An Aim director told me years ago what the fee was to release an RNS. Google it. It’s free to join the service but it’s pay as you go for news release. There are different models. Like most regulations they are constantly being reviewed and updated. We’ve had around 12 RNS for UBS this year relating to their 5 percent holding. Seems a bit excessive. Just because a company delists or goes out of business and doesn’t mean there are no administrative costs to be paid. It’s the share holder that gets BA! |
Well said. |
RNSes don't cost money this is a PI fallacy. How do you think bankrupt companies in administration still issue RNSes ?
UBS are probably simply a prime broker to various hedge funds who may be doing the buying/selling etc
Companies should focus on running their business not worrying about white-noise of trading in their stock |
I think the company should release a statement about UBS seemingly pointless buying and selling of a stake in Renx, resulting in a constant stream of unnecessary RNS wasting company money.The presentation sounds encouraging. The news is a bit more vague. I guess this sector is in limbo until the orange one is turned into fruit juice before he sends the world economy to oblivion. |
Good update. |
 Good event well worth the effort Rather surprised by the low level attendance. I had no idea Renx had hit over £11 a while back. Thats what happens when you mess with the nasdaq!good to meet some other investors all at different stages of its cycle, but clearly some long term holders too. Julian was the largest participant in the placing after he regained the reigns. It was helpful to get the history and debacle which nearly screwed up one of the best diagnostic propositions or ‘the best I have been involved with in my career’ as Julian emphasised on more than one occasion. So while £11 was clearly a ludicrous valuation so to is 9p , which is why funds like Ruffer (we never loose money)came in for 5% in the placing, not one of their usual kind of companies. More than happy to top up at these levels. Cant see much better risk/reward elsewhere at the moment. Quite like POS, but think the management are number 1 in the interests of shareholders.GMS looks quite solid once warrants and Seafox are sorted. Always some kind of pebble in the shoe with investing |
Road Show :
an in-person presentation will take place at 5:30 pm GMT on Tuesday, March 25, 2025. This event, also led by Julian Baines, will be held at 75 King William Street, London, and is open to existing and potential shareholders. Attendees are welcome from 5:15 pm, with the presentation commencing at 5:30 pm, followed by refreshments. |
Solid presentation.
Outlook looks very promising from a very low baseline - execution is key but it is all to play for. |
They seem to be achieving what they said they would with ease. More than doubling the number of doctors signing up orders and halving admin costs and slashing the cash burn. will that be good enough for this bs market, who can say? |
The head honcho seemed confident of sales traction a few months ago - will know soon if that was misplaced or not. |
Silverblade
Posts: 1,636
Price: 9.75
No Opinion
Latest Director Purchase
Today 11:29
Fergus Fleming picked up a further 25K shares on Friday to add to the 80K he picked up as part of the placing. Now holds just under 700K shares (Latest RNS appears to have missed out his placing purchase). This adds to the recent market purchases made by James McCullough, Julian Baines, Catherine Coste, Howard Doran and Chris Scott. Whilst the purchases are all small, in combination they represent the first time I can remember coordinated stock purchases by company directors. I have added to my position here and am starting to feel more optimistic about 2025 than I have for while. ATB to all who regularly post here. SB |
Very positive interview |
Question answered in interview on Vox with JB. No need for another fund raise. Sales are going well and accelerating. |
They can't buy whilst in possession of endogenous inside information but they have let it be known they expect the new US Health agency leads under Trump to be favourable to their business so I guess they can buy based on that exogenous public information. |
BoD been buying everyday recently, so more Tr-1buys tonight? |
The JB effect! Should have bought more I suppose but the risk was looking ominous. I got no reply to my question about conflicting RNS and whether they do or do not need future funding. I guess they don’t actually know for sure. Seems like not in the next 12 months and by then they could be flying . Lot of uncertainties in USA , but if they want a healthier fitter society then Renx can help with that and reduce their costs. Same applies to Vrci. |
director buys |
Can’t argue with any of that but here’s the main issue . Aim and the uk are in the poop. No traders no interest in any share . Aim only ever worked on hype and there’s no hype so unfortunately no hope |
Ah! Yes, I see that in the RNS although couldn't see it in the full Annual Report.
The RNS says "Renalytix is funded and projected to deliver anticipated profitability in two years with no further funding requirements"
So, no further fundraises within two years IF their projections are correct.
Of course, they may well not be. And profitability maybe after EDITA or some other spurious expenses / costs.
I would say that going from 2024's $33.5m loss on turnover of $2.3m to profitability in two years is going to be a tall order.
Don't get me wrong, I would like them to - I hold.
Good to have Julian Baines back onboard. |
Renalytix have said that they "believe that the company will be able to achieve profitability in 2 years" and "raised enough money to secure the run through profitability."
As far as I can see, they don't explicitly rule another fund raise out and it would be foolish of them to do so. |
Sounds like a wild guess. Debt reduced by 80 percent, profitability within 2 years and no further cash raise. Interesting comments about Trump and Kennedy commitment to fighting kidney disease. |
I’m going to take a wild guess and say ….no |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
